The global eye care market size was estimated at USD 22.0 billion in 2025 and is projected to reach USD 28.8 billion by 2033, growing at a CAGR of 3.4% from 2026 to 2033. The market is driven by a rising number of people suffering from eye-related disorders, an aging population, technological advancements, and increasing awareness about eye care.
The increasing prevalence of vision disorders, particularly vision impairment and presbyopia, presents a significant opportunity for the industry. With around 2.2 billion people worldwide suffering from vision impairment, and an estimated 1.09 billion cases of presbyopia affecting the middle-aged to elderly population, the demand for vision care services and products is poised to grow. The primary causes of vision impairment such as refractive errors and cataracts are largely preventable or treatable, indicating a vast untapped market for corrective lenses, surgical procedures, and other interventions. The economic burden of vision impairment, estimated at USD 411 billion annually in lost productivity, underscores the importance of accessible and affordable care solutions. The WHO’s SPECS 2030 initiative aims to increase access to refractive error services by 40%, further highlighting the industry’s potential. Given the demographic shifts towards an aging population and the rising awareness of eye health, the industry is well-positioned for growth, driven by the need to address the global vision disorder epidemic.
Cataract surgery is the number one surgery performed globally, with 28 million procedures each year. But only 10-15% of patients are getting advanced optical IOLs specifically designed for astigmatism and presbyopia.
“We are starting the new year with the launch of another complex high-value product, which will help drive our continued growth, ophthalmic products represent a less crowded and more durable category, and we continue to expand our portfolio of affordable medicines.”
” Andy Boyer, Executive Vice President, Chief Commercial Officer - Generics. “
Government initiatives involving the Vision and Eye Health Surveillance System (VEHSS) have driven advancements in the industry since its inception. VEHSS has evolved to include additional years of data, condition-specific composite estimates for vision impairment, blindness, and age-related macular degeneration, along with mapping and other data visualization capabilities. In 2022, VEHSS expanded its capabilities to stratify American Community Survey estimates of vision impairment and blindness by social determinants of health, including poverty, unemployment, and other disabilities.
This initiative has resulted in numerous peer-reviewed publications and reports, highlighting its impact on understanding, and addressing vision loss and conditions in the U.S. In addition, rising public health initiatives and a focus on preventive healthcare are making people more aware of the importance of regular eye exams. In May 2024, The Canadian Association of Optometrists (CAO) launched a nationwide digital campaign to remind people about the importance of eye health. This campaign, supported by provincial optometry groups, encourages Canadians to schedule regular eye exams with their optometrist.
This product will be delivered within 1-3 business days.
The increasing prevalence of vision disorders, particularly vision impairment and presbyopia, presents a significant opportunity for the industry. With around 2.2 billion people worldwide suffering from vision impairment, and an estimated 1.09 billion cases of presbyopia affecting the middle-aged to elderly population, the demand for vision care services and products is poised to grow. The primary causes of vision impairment such as refractive errors and cataracts are largely preventable or treatable, indicating a vast untapped market for corrective lenses, surgical procedures, and other interventions. The economic burden of vision impairment, estimated at USD 411 billion annually in lost productivity, underscores the importance of accessible and affordable care solutions. The WHO’s SPECS 2030 initiative aims to increase access to refractive error services by 40%, further highlighting the industry’s potential. Given the demographic shifts towards an aging population and the rising awareness of eye health, the industry is well-positioned for growth, driven by the need to address the global vision disorder epidemic.
Cataract surgery is the number one surgery performed globally, with 28 million procedures each year. But only 10-15% of patients are getting advanced optical IOLs specifically designed for astigmatism and presbyopia.
Jacqueline Henderson, President Vision, EMEA, Johnson & Johnson
Technological advancements in vision care, including smart contact lenses, drug-delivering contact lenses, multifocal and extended depth of focus (EDOF) intraocular lenses (IOLs), automated refraction systems, and digital retinal imaging, represent significant drivers for the industry. These innovations enhance the functionality and efficacy of products, as well as treat and manage ocular health. For instance, smart contact lenses promise to revolutionize diabetes management by enabling continuous glucose monitoring, while drug-delivering contact lenses offer a novel approach to treating ocular surface diseases. Multifocal and EDOF IOLs improve post-cataract surgery outcomes by providing clearer vision at various distances, reducing dependency on reading glasses. For instance, in June 2023, Novaliq announced FDA approval of VEVYE (Cyclosporine Ophthalmic Solution) 0.1% for treating dry eye disease signs and symptoms, marking the first cyclosporine solution with proven efficacy in 4 weeks. In addition, in February 2024, Johnson & Johnson MedTech launched the TECNIS PureSee presbyopia-correcting intraocular lens in EMEA. This next-generation lens features a purely refractive design, delivering uninterrupted, high-quality vision with excellent low-light performance and minimal visual symptoms, enhancing cataract surgery outcomes for patients and surgeons. In addition, automated refraction systems streamline the prescription process, and digital retinal imaging aids during early detection and monitoring of diseases. These advancements drive the market forward by addressing unmet needs, and opening new markets, thereby fostering innovation and growth in the sector.“We are starting the new year with the launch of another complex high-value product, which will help drive our continued growth, ophthalmic products represent a less crowded and more durable category, and we continue to expand our portfolio of affordable medicines.”
” Andy Boyer, Executive Vice President, Chief Commercial Officer - Generics. “
Government initiatives involving the Vision and Eye Health Surveillance System (VEHSS) have driven advancements in the industry since its inception. VEHSS has evolved to include additional years of data, condition-specific composite estimates for vision impairment, blindness, and age-related macular degeneration, along with mapping and other data visualization capabilities. In 2022, VEHSS expanded its capabilities to stratify American Community Survey estimates of vision impairment and blindness by social determinants of health, including poverty, unemployment, and other disabilities.
This initiative has resulted in numerous peer-reviewed publications and reports, highlighting its impact on understanding, and addressing vision loss and conditions in the U.S. In addition, rising public health initiatives and a focus on preventive healthcare are making people more aware of the importance of regular eye exams. In May 2024, The Canadian Association of Optometrists (CAO) launched a nationwide digital campaign to remind people about the importance of eye health. This campaign, supported by provincial optometry groups, encourages Canadians to schedule regular eye exams with their optometrist.
Global Eye Care Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global eye care market report based on product, mode of purchase, distribution channel, and region:Product Outlook (Revenue, USD Million, 2021-2033)
- Contact Lens
- Intraocular Lens
- Ocular Health Products
- Others
Mode of Purchase Outlook (Revenue, USD Million, 2021-2033)
- Over-The-Counter (OTC) Products
- Prescribed (Rx) Products
Distribution Channel Outlook (Revenue, USD Million, 2021-2033)
- Hospitals & Clinics
- Retail Stores
- Online Stores
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Eye Care Market Variables, Trends & Scope
Chapter 4. Eye Care Market: Product Estimates & Trend Analysis
Chapter 5. Eye Care Market: Mode of Purchase Estimates & Trend Analysis
Chapter 6. Eye Care Market: Distribution Channel Estimates & Trend Analysis
Chapter 7. Eye Care Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Alcon, Inc.
- Johnson and Johnson Eye Care, Inc.
- Bausch & Lomb Incorporated
- Carl Zeiss Meditec AG (ZEISS International)
- Essilor International
- CooperVision
- HOYA CORPORATION
- Rayner Group
- STAAR SURGICAL
- Novartis AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 130 |
| Published | May 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 22 Billion |
| Forecasted Market Value ( USD | $ 28.8 Billion |
| Compound Annual Growth Rate | 3.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
